OTC Products · LP-220
Diclofenac sodium Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-220OTC Products
- Generic identity
- Diclofenac sodiumTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-220
- Generic ingredient
- Diclofenac sodium
- Dosage form
- Tablet
- Proposed strength
- 50 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- OTC Products
About Diclofenac sodium
Diclofenac sodium is a non-steroidal anti-inflammatory drug used for selected pain and inflammatory conditions. It reduces prostaglandin production and has gastrointestinal, cardiovascular and renal risks. An oral tablet differs from topical diclofenac gels or other injectable and rectal forms. The salt and release characteristics need verification because the same ingredient family can be supplied in several clinically different presentations.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional selection considers the cause of pain, functional impact, expected exposure and safer alternatives in the particular patient. Symptom relief does not treat every underlying cause of pain. A tablet should not be combined casually with another NSAID or assumed safe because a topical product was previously tolerated. This catalogue gives ingredient and formulation education without a treatment duration, dosing instruction or claim that this candidate is appropriate for all musculoskeletal conditions.
Important safety considerations
Gastrointestinal bleeding or ulceration, cardiovascular events, fluid retention and kidney injury are important risks. Liver effects and severe allergic or skin reactions can occur. Review previous ulcer or bleeding, cardiovascular disease, renal impairment, asthma reactions to NSAIDs and medicines affecting bleeding or kidney function. Pregnancy-related restrictions require current professional advice. Black stools, vomiting blood, chest symptoms or severe allergy need urgent assessment.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source states diclofenac sodium 50 mg tablets without identifying enteric coating or release type. Do not assume delayed or prolonged release, or suitability for crushing. Verify the exact tablet formulation and label before substitution.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review pain diagnosis, gastrointestinal and cardiovascular history, renal and liver risks, pregnancy and interactions. Confirm the exact salt and release formulation.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Diclofenac sodium
- Dosage form / presentation
- Tablet
- Catalogue strength
- 50 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- OTC Products
Layer 02
Unresolved product-specific fields
- Tablet release type/coating unspecified. Do not silently describe as enteric-coated.
- Exact release/coating/scoring characteristics and formulation-specific administration instructions require controlled product documentation where applicable.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: diclofenacpublic health service medicine information
- NHS: diclofenac adverse effectsgovernment or public health guidance
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-220, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-220.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.